Establishment of a Multi‐Stage In Vitro Screening Platform to Identify Candidate Compounds for Intestinal Mucosal Damage in Inflammatory Bowel Disease
Advanced Healthcare Materials · 16.11.2026
DOI: 10.1002/adhm.71984 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 16.11.2026. Verfasst von Fuki Yokoi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Synthetic Human Body System, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Japan Science and Technology Agency.
Abstract (Originalsprache)
Mucosal healing is a key therapeutic goal in inflammatory bowel disease (IBD), which is characterized by mucosal lesions in the gastrointestinal tract. For IBD drug development, it is important to identify multiple compounds with strong effects on mucosal injury and different mechanisms of action. Here, we established an intestinal organoid‐based assay to evaluate cytokine‐induced inflammatory and epithelial stress responses. We also developed an intestinal microphysiological system (intestinal MPS)‐based assay for quantitative evaluation of cytokine‐induced changes in mucosal architecture. By integrating these assays, we constructed a multi‐stage screening platform to identify candidate compounds that suppress inflammatory responses and preserve mucosal architecture. Tofacitinib, an approved IBD drug, showed positive effects in these assays, supporting the relevance of this platform. Although organoid‐based screening identified pimitespib as a candidate compound, pimitespib did not improve mucosal architecture in the intestinal MPS. Consistently, pimitespib failed to restore mucosal morphology in an IBD mouse model. These findings suggest that combining intestinal organoids with an intestinal MPS may help identify candidate compounds that suppress inflammatory responses while preserving mucosal architecture.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Synthetic Human Body System, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
- School of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Center For iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
- Research Institute, Nozaki Tokushukai Hospital, Osaka, Japan.
- Institute For the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
- Department of State-of-the-art and International Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Akira Ohta, Rina Hashimoto, Ryosuke Negoro, Kazuo Takayama
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Yokoi, F., Deguchi, S., Fuse, H., Ohta, A., Hashimoto, R., Kosugi, K., Negoro, R., Yamamoto, T., & Takayama, K. (2026). Establishment of a Multi‐Stage In Vitro Screening Platform to Identify Candidate Compounds for Intestinal Mucosal Damage in Inflammatory Bowel Disease. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71984
Vancouver
Yokoi F, Deguchi S, Fuse H, Ohta A, Hashimoto R, Kosugi K, et al. Establishment of a Multi‐Stage In Vitro Screening Platform to Identify Candidate Compounds for Intestinal Mucosal Damage in Inflammatory Bowel Disease. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71984
BibTeX
@article{Yokoi2026,
author = {Yokoi, Fuki and Deguchi, Sayaka and Fuse, Hiromitsu and Ohta, Akira and Hashimoto, Rina and Kosugi, Kaori and Negoro, Ryosuke and Yamamoto, Takuya and Takayama, Kazuo},
title = {Establishment of a Multi‐Stage In Vitro Screening Platform to Identify Candidate Compounds for Intestinal Mucosal Damage in Inflammatory Bowel Disease},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71984}
}
EUVIMED